Skip to main content

HomeLegalRetatrutide in California

Educational — Not Legal AdviceUpdated

Retatrutide in California: Legal Status & Provider Guide (2026)

Quick Answer

Retatrutide is a prescription substance in the United States. Retatrutide is an investigational triple-receptor agonist (GIP/GLP-1/glucagon) with no FDA approval. It cannot legally be compounded under federal law. Commercial availability outside of clinical trials is not authorized by the FDA. In California, compounding is governed by the California State Board of Pharmacy (CSBP). California allows nurse practitioners and physician assistants with standardized procedures or physician collaboration to prescribe compounded peptides. California's telehealth laws (AB 2019 and subsequent legislation) require an established patient-provider relationship before prescribing. Out-of-state prescribers cannot prescribe to California patients without a California license.

Federal Legal Status

FDA Approval Status

Not FDA-approved. Retatrutide is in Phase III clinical trials as of 2026. No NDA filed.

Compounding Pharmacy Rules (Federal)

Retatrutide is not FDA-approved and is not on any bulk substances list for compounding. It is an investigational drug in active Phase III trials. Compounding pharmacies cannot legally compound retatrutide under federal law. Providers offering it outside of a formal clinical trial operate without federal regulatory authorization.

Also Known As

LY3437943

Primary Research Areas

  • Weight loss
  • Obesity management
  • Metabolic syndrome
  • Type 2 diabetes

California Pharmacy Board & Compounding Rules

Compounding Overview

The California State Board of Pharmacy enforces strict compounding standards, often exceeding federal minimums. California has its own sterile compounding licensure category and requires all sterile compounding pharmacies to hold a specialty license. California pharmacies must comply with USP 797 (sterile) and USP 795 (non-sterile) standards. The California Medical Board also imposes strict telemedicine prescribing standards that affect peptide clinics operating as telehealth platforms serving California residents.

Notable Rules

  • California requires a specialty sterile compounding license in addition to a standard pharmacy license.
  • USP 797 and 795 compliance is mandatory for all California-licensed compounding pharmacies.
  • The California Medical Board has specific guidance on prescribing practices for "off-label" and compounded medications.
  • Out-of-state pharmacies must be licensed by CSBP to ship prescription compounds into California.
  • California prohibits prescription dispensing without an established patient-provider relationship in most telehealth contexts.

Prescribing Requirements in California

California allows nurse practitioners and physician assistants with standardized procedures or physician collaboration to prescribe compounded peptides. California's telehealth laws (AB 2019 and subsequent legislation) require an established patient-provider relationship before prescribing. Out-of-state prescribers cannot prescribe to California patients without a California license.

About Retatrutide

Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. Phase II trials reported average weight loss of approximately 24% at the highest dose over 48 weeks. Phase III trials are ongoing as of 2026.

For more research information, mechanism of action, and provider availability, see the Retatrutide research profile on PeptideBase.

Frequently Asked Questions

Is retatrutide available to the public?
Retatrutide is not FDA-approved and is not legally available outside of clinical trials. Some providers may offer it under research or "off-label investigational" frameworks, but this carries significant legal and safety risk. Verify any provider's authorization carefully.
When might retatrutide receive FDA approval?
Phase III trials are ongoing as of 2026. FDA approval, if granted, would follow Phase III completion and NDA review — typically 1–3 years after Phase III initiation. Monitor ClinicalTrials.gov for updates.

Retatrutide Providers in California

5 providers in the PeptideBase directory offer Retatrutide in California. Always verify current offerings directly with the provider.

Retatrutide Legal Status in Other States

Pharmacy board rules and compounding regulations vary by state. Compare Retatrutide legal status across other major markets:

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.

Free Guide

The Peptide Research Digest

Get our free provider vetting guide — plus weekly research briefings on peptide sourcing, COA verification, and clinical developments.

No spam.